[The efficacy of Sulodexide--a low-molecular heparin--in the therapy of diabetic nephropathy].
A novel pathogenetic approach to treatment of diabetic nephropathy (DN) as a severe complication of diabetes mellitus is aimed at inhibiting DN progression or its involution by means of reestablishment of heparan sulfate synthesis by glycosaminoglycane drug. In the study of 9 patients with microalbuminuria and 9 with proteinuria this drug was low-molecular heparin-sulodexide (Alfa-Wasserman, Italy). The treatment course of 3 weeks resulted in albuminuria fall in 89% of patients. In patients with microalbuminuria protein excretion returned to normal values in a week of treatment. This effect was persistent after the drug discontinuation. This was not so for protein excretion in proteinuria patients which became low after 3 weeks of treatment, but the effect was not long-lasting. The authors believe that glycosaminoglycanes hold great promise in DN, especially at early stages of renal diabetic affection.
Shestakova
M V
MV
Chugunova
L A
LA
Vorontsov
A V
AV
Dedov
I I
II
D000293:Adolescent; D000328:Adult; D000419:Albuminuria / Q000188:drug therapy* / Q000652:urine; D002908:Chronic Disease; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000652:urine; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000652:urine; D006025:Glycosaminoglycans / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008875:Middle Aged; D013997:Time Factors
D006025:Glycosaminoglycans; D006495:Heparin, Low-Molecular-Weight; D007004:Hypoglycemic Agents; C007858:glucuronyl glucosamine glycan sulfate